TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15604915

Group type: EXPERIMENTAL
Intervention: MM (100% AM and 20% FM)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AM2
Number of subjects: 70

Group type: COMPARATOR
Intervention: AM
Number of subjects: 70

Group type: COMPARATOR
Intervention: FM
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MM and AM2
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall responses
Number of subjects: 70
Study: 11289051

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg once daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nifedipine 10 mg retard twice daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: All groups (Enalapril, Nifedipine, Placebo)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Baseline AER
Number of subjects: 54
Study: 9647874

Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 377
Study: 7847107

Group type: EXPERIMENTAL
Intervention: Cyclo‐Progynova, containing 0.5 mg of norgestrel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Climen, containing 1 mg of cyproterone acetate (CPA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatment regimens
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CPA‐containing preparation
Number of subjects: 20
Study: 1971778

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (4.0 micrograms/kg min) for 17 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion (0.5 micrograms/kg min) for 8 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study: 232314

Group type: EXPERIMENTAL
Intervention: Continued cyclical chemotherapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: No further chemotherapy until relapse
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide, vincristine, procarbazine, methotrexate)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radiotherapy or palliative treatment for non-responders
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Indicators of non-response to chemotherapy
Number of subjects: 56
Study: 31358390

Group type: EXPERIMENTAL
Intervention: Aspirin use (propensity score matched)
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Aspirin use (quintile 5)
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Control group (non-users of aspirin)
Number of subjects: 1950
Study: 28273894

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (3 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 60
Study: 26714778

Group type: EXPERIMENTAL
Intervention: Silymarin (BIO‐C®)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24721161

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 2866

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 2866
Study: 21946342

Group type: EXPERIMENTAL
Intervention: Maternal change in step counts
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Paternal change in step counts
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Day of week effect on maternal change
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Day of week effect on paternal change
Number of subjects: 83
Study: 19136481

Group type: EXPERIMENTAL
Intervention: Patient-Delivered Partner Therapy (PDPT) - 1 g azithromycin for partners
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Postal Testing Kits (PTK) - partners post urine for testing
Number of subjects: 330

Group type: COMPARATOR
Intervention: Patient Referral
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Postal Testing Kits (PTK)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Patient-Delivered Partner Therapy (PDPT)
Number of subjects: 330
Study: 17504175

Group type: EXPERIMENTAL
Intervention: Structured treatment interruptions (STI group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (CTRL group)
Number of subjects: 112
Study: 15207419

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12514907

Group type: EXPERIMENTAL
Intervention: Partial laryngectomy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Laryngovideoscopy (Lvs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Airflow parameters (PIF, FIF50, FIV1, FIV1%/N FEV1, % Rz/N PEF)
Number of subjects: 82
Study: 9519637

Group type: COMPARATOR
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 16
Study: 8082624

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 2903105

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 188
Study: 31262226

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe PsO patients with treated anxiety/depression (≥1 anxiety or depression diagnosis plus any anxiolytics, antidepressants, or antipsychotics within 30 days)
Number of subjects: 69644

Group type: COMPARATOR
Intervention: Moderate-to-severe PsO patients without anxiety/depression
Number of subjects: 69644

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe PsO patients with treated anxiety/depression
Number of subjects: 69644

Group type: COMPARATOR
Intervention: Moderate-to-severe PsO patients without treated anxiety/depression
Number of subjects: 69644
Study: 28467333

Group type: EXPERIMENTAL
Intervention: Topical phenytoin (5 mg/L in 0.9% NaCl solution), applied for 3 hours every 12 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 19
Study: 25248348

Group type: EXPERIMENTAL
Intervention: Previously vaccinated hemodialyzed patients
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Previously unvaccinated hemodialyzed patients
Number of subjects: 134

Group type: COMPARATOR
Intervention: Previously vaccinated non‐hemodialyzed patients
Number of subjects: 134
Study: 24622413

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 50 μg per day
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 134
Study: 21885586

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) model of supported employment
Number of subjects: 91

Group type: COMPARATOR
Intervention: High levels of cognitive symptoms
Number of subjects: 91
Study: 19478638

Group type: EXPERIMENTAL
Intervention: Dynamic enhanced computed tomography (CT) after neoadjuvant chemotherapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cutoff NME of 40 Hounsfield for differentiating nonmetastasized and metastasized axilla nodal status
Number of subjects: 39
Study: 17927495

Group type: EXPERIMENTAL
Intervention: Lycopene alone (15 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lycopene plus soy isoflavones (40 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 71
Study: 15013832

Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 91
Study: 11901629

Group type: EXPERIMENTAL
Intervention: Nimbex (new non-depolarizing myorelaxant)
Number of subjects: 0
Study: 9246023

Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (general)
Number of subjects: 0
Study: 8375366

Group type: EXPERIMENTAL
Intervention: Facial cooling at 35% VO2max (FC35)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Facial cooling at 70% VO2max (FC70)
Number of subjects: 5
Study: 2428592

Group type: EXPERIMENTAL
Intervention: Stimulus presentation rates of 0.5/sec, 1/sec, 5/sec, 8/sec, and 10/sec
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mastoid and sternovertebral references
Number of subjects: 7
Study: 30756120

Group type: EXPERIMENTAL
Intervention: Memory Clinic intervention
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Community engagement and physician outreach
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Resource education and staff training
Number of subjects: 110
Study: 29108721

Group type: EXPERIMENTAL
Intervention: Endoscopic step-up approach
Number of subjects: 98

Group type: COMPARATOR
Intervention: Surgical step-up approach
Number of subjects: 98
Study: 27484126

Group type: EXPERIMENTAL
Intervention: Guided self-help exercise program built into the application 'In Tune without Cords'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-care education program only
Number of subjects: 0
Study: 24247410

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus, followed by an infusion of 1.5 μg/kg/min)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 54
Study: 23144486

Group type: EXPERIMENTAL
Intervention: Independent, interactive media module for dental morphology instruction
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional classroom method with lectures
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Independent, interactive media module
Number of subjects: 67
Study: 19819617

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Combination of epirubicin and interferon-alpha2b
Number of subjects: 250
Study: 17667482

Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills Program
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 16596911

Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 14

Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 14
Study: 11904068

Group type: EXPERIMENTAL
Intervention: Wilsonii injecta
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional methods (Group A)
Number of subjects: 120
Study: 10658943

Group type: EXPERIMENTAL
Intervention: Valsartan (80-160 mg/day orally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enalapril (20-40 mg/day orally)
Number of subjects: 24
Study: 8574257

Group type: EXPERIMENTAL
Intervention: Norgestimate 250 micrograms + ethinyl estradiol (EE) 35 micrograms (Cilest)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Norgestimate 180/215/250 micrograms + EE 35 micrograms (Tricilest)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + EE 20 micrograms (Marvelon)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + EE 30 micrograms (Mercilon)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Gestodene 75 micrograms + EE 30 micrograms (Femovan)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Gestodene 50/70/100 micrograms + EE 30/40/30 micrograms (Trifemovan)
Number of subjects: 466
Study: 2225430

Group type: EXPERIMENTAL
Intervention: Deferoxamine (30 mg/kg body weight intravenously starting 30 minutes before bypass for 4 hours and 250 mg/l in cardioplegic solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no deferoxamine treatment)
Number of subjects: 20
Study: 518286

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) at a daily dose of 120 mg for 8 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 29
Study: 31864683

Group type: EXPERIMENTAL
Intervention: Hysterectomy (HT) after RCT and IGABT
Number of subjects: 145

Group type: COMPARATOR
Intervention: Definitive RCT and IGABT
Number of subjects: 145
Study: 31182440

Group type: EXPERIMENTAL
Intervention: Active pulsed low-frequency magnetic field (PLFMF) therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 200
Study: 28770512

Group type: EXPERIMENTAL
Intervention: Early intensive mobilization
Number of subjects: 120

Group type: COMPARATOR
Intervention: Early conventional mobilization
Number of subjects: 120
Study: 25873089

Group type: EXPERIMENTAL
Intervention: PPF-LLIN (containing 2% permethrin and 1% pyriproxyfen w/w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% permethrin-treated LLINs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPF-LLIN
Number of subjects: 0
Study: 22895871

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sitting (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Standing
Number of subjects: 15
Study: 21943207

Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling (up to seven calls over three months, including cognitive-behavioral skill building and Motivational Interviewing)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control condition (standard brochure for smoking cessation)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 512
Study: 20026830

Group type: EXPERIMENTAL
Intervention: Endoluminal stenting followed by laparoscopic resection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Emergency open surgery
Number of subjects: 48
Study: 16318996

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 12
Study: 15526719

Group type: EXPERIMENTAL
Intervention: Growth hormone deficiency (GHD) patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy children (control)
Number of subjects: 25
Study: 11407799

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg, administered subcutaneously twice daily)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Warfarin (adjusted to an international normalized ratio of 2 to 3)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 349

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 349
Study: 9058616

Group type: EXPERIMENTAL
Intervention: Ganciclovir, foscarnet, and cidofovir (systemic antiviral agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct delivery of an antiviral agent into the vitreous of an infected eye
Number of subjects: 0
Study: 7959186

Group type: EXPERIMENTAL
Intervention: Pneumatic dilator
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metallic dilator
Number of subjects: 41
Study: 3110562

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate (E2V) daily for 6 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4 mg oestradiol valerate (E2V) daily for 6 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate (E2V) daily for 3 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4 mg oestradiol valerate (E2V) daily for 3 months
Number of subjects: 19
Study: 30369076

Group type: EXPERIMENTAL
Intervention: WCK 2349 (2,600 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29940888

Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil (1060 mg EPA plus 274 mg DHA)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (900 mg DHA plus 180 mg EPA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Soy oil placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil and DHA-rich fish oil
Number of subjects: 126
Study: 27160363

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg 3 times a day for 3 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg 3 times a day for 3 days)
Number of subjects: 20
Study: 25245386

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (calcium channel blocker-based or β-blocker-based)
Number of subjects: 251
Study: 22673596

Group type: EXPERIMENTAL
Intervention: GPC 1000 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20493274

Group type: EXPERIMENTAL
Intervention: SE36/AHG (50 and 100 microg doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18822979

Group type: EXPERIMENTAL
Intervention: Regulating kidney and smoothing liver needling group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Routine acupuncture group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chinese medicine group
Number of subjects: 200
Study: 15580060

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 60% of individual sustained maximal inspiratory pressure (SMIP) for 10 weeks, three times weekly.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group exercised at 15% of SMIP for 10 weeks, three times weekly.
Number of subjects: 35
Study: 11721719

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors, heparin according to TIMI 14 trial, and aspirin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo, rt-PA 100 mg, standard heparin treatment, and aspirin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 9453422

Group type: EXPERIMENTAL
Intervention: Ultrasonographic score
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Ultrasonographic score based on liver surface nodularity and portal flow velocity
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Ultrasonographic diagnosis of cirrhosis
Number of subjects: 212
Study: 7894208

Group type: EXPERIMENTAL
Intervention: D-Tryptophan-6 luteinizing hormone releasing hormone (D-Trp-6-LH-RH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 3295302

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30012107

Group type: EXPERIMENTAL
Intervention: Serum free light chain level >800 mg/L
Number of subjects: 1595

Group type: COMPARATOR
Intervention: eGFR ≥60 ml/min/1.73 m2 (no RI)
Number of subjects: 1595

Group type: COMPARATOR
Intervention: eGFR 30-59 ml/min/1.73 m2 (mild to moderate RI)
Number of subjects: 1595

Group type: COMPARATOR
Intervention: eGFR <30 ml/min/1.73 m2 (severe RI)
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Higher serum FLC level, female gender, older age
Number of subjects: 1595
Study: 25310244

Group type: EXPERIMENTAL
Intervention: Webcast lectures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live lectures
Number of subjects: 0
Study: 25054399

Group type: EXPERIMENTAL
Intervention: Local anesthetic alone (1.5 mL of 1% preservative-free lidocaine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local anesthetic with steroid (1% lidocaine and 3 mg betamethasone)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local anesthetic alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local anesthetic with steroid
Number of subjects: 120
Study: 23747768

Group type: EXPERIMENTAL
Intervention: qili qiangxin capsules
Number of subjects: 512

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 512
Study: 20354688

Group type: EXPERIMENTAL
Intervention: Paroxetine 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18191056

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study: 16933160

Group type: EXPERIMENTAL
Intervention: Guidewires with surface markers (marker group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional guidewires (control group)
Number of subjects: 60
Study: 14568737

Group type: EXPERIMENTAL
Intervention: Nevirapine plus zidovudine
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Nevirapine alone
Number of subjects: 1119
Study: 10986188

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenothiazines, lignocaine (lidocaine), ketorolac, ergot alkaloids, metoclopramide hydrochloride, triptans, haloperidol, pethidine (meperidine hydrochloride), magnesium sulfate
Number of subjects: 0
Study: 8757203

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 micrograms, once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1343475

Group type: EXPERIMENTAL
Intervention: Operative laparoscopy in ART procedures (GIFT, ZIFT, TET)
Number of subjects: 0
Study: 3905326

Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 30

Group type: COMPARATOR
Intervention: HCT-triamterene
Number of subjects: 30
Study: 29966428

Group type: EXPERIMENTAL
Intervention: Clustered campaign extended care program (12 sessions delivered in three, 4‐week clusters)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Self-directed control
Number of subjects: 269
Study: 30868305

Group type: EXPERIMENTAL
Intervention: Spreader flaps used in combination with spreader grafts (Group 1)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Spreader flaps used alone (Group 2)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Spreader grafts used alone (Group 3)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Neither spreader flaps nor grafts used (Group 4)
Number of subjects: 264
Study: 30511947

Group type: EXPERIMENTAL
Intervention: Eccentric PT at posttest (80.0% of pretest)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eccentric PT at 5-min recovery (87.8% of pretest)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Muscle blood flow at posttest
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Muscle blood flow recovery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neuromuscular responses
Number of subjects: 36